NSE: RPGLIFE · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
RPG Life Sciences Limited is an integrated pharmaceutical company that develops, manufactures, and markets branded formulations, generics, and synthetic active pharmaceutical ingredients (APIs). The company operates across diverse therapeutic categories, including nephrology, oncology, and immunosuppressants, serving both domestic and international markets.
The company generates revenue through the sale of finished dosage formulations and synthetic APIs, leveraging its manufacturing capabilities to serve various medical specialties. It operates as a subsidiary of Nucleus Life Trust and maintains a broad portfolio of therapeutic products.
Growth is driven by the expansion of its branded formulations portfolio and the continued development of synthetic APIs for global markets. The company focuses on high-growth therapeutic areas such as nephrology and rheumatology to sustain its market position.
Unlock AI insights, financials, peers and live data on RPG Life Sciences Limited and 5,000+ companies — free.
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
RPG Life Sciences LimitedRPGLIFE | ₹4,217 Cr | 38.0× | 22.80 | — | 23.7% | 16.2% | 16.9% | +6.1% |
Novartis IndiaNOVARTIND | ₹4,241 Cr | 43.4× | 30.21 | 5.4% | 37.4% | 12.2% | 16.7% | +97.9% |
Jeena Sikho Lifecare LimitedJSLL | ₹4,241 Cr | 17.9× | 10.99 | — | 45.2% | 50.6% | 58.2% | -54.0% |
Zota Health Care LimitedZOTA | ₹4,215 Cr | -38.7× | 365.18 | 78.9% | 1.9% | -22.7% | -14.6% | -19.5% |
Gufic Biosciences LimitedGUFICBIO | ₹4,178 Cr | 56.9× | 26.98 | 16.7% | 17.0% | 11.6% | 16.9% | +28.0% |
Aarti Drugs LimitedAARTIDRUGS | ₹4,142 Cr | 21.7× | 14.01 | — | 12.6% | 13.1% | 14.5% | -7.6% |
As of Q2 FY27
RPG Life Sciences Limited
NSE: RPGLIFE · Pharmaceuticals
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
RPG Life Sciences Limited is an integrated pharmaceutical company that develops, manufactures, and markets branded formulations, generics, and synthetic active pharmaceutical ingredients (APIs). The company operates across diverse therapeutic categories, including nephrology, oncology, and immunosuppressants, serving both domestic and international markets.
The company generates revenue through the sale of finished dosage formulations and synthetic APIs, leveraging its manufacturing capabilities to serve various medical specialties. It operates as a subsidiary of Nucleus Life Trust and maintains a broad portfolio of therapeutic products.
Growth is driven by the expansion of its branded formulations portfolio and the continued development of synthetic APIs for global markets. The company focuses on high-growth therapeutic areas such as nephrology and rheumatology to sustain its market position.
Unlock AI insights, financials, peers and live data on RPG Life Sciences Limited and 5,000+ companies — free.
As of Q2 FY27